发布求助
搜索
全部 求助中 待确认 已完结
其它数据库
求助中 Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Fovinaciclib for First-Line Therapy of Advanced Breast Cancer A Randomized Clinical Tria
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Is There Still Room for Monotherapy in EGFR-Mutated Non–Small Cell Lung Cancer?
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Pembrolizumab-Chemotherapy Versus Pembrolizumab in Head and Neck Squamous Cell Carcinoma: A PD-L1 CPS-Stratified Analysis of Updated KEYNOTE-048 Data
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
求助中 Wearable ultrasound devices for health monitoring: a closed-loop co-design framework from materials to algorithms and applications
用户niBWSy 用户niBWSy
2026-09-02
10
我要应助
其它数据库
求助中 Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Cancer burden and control in China: landscape, trends and challenges
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助